MX2020005005A - Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas. - Google Patents

Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas.

Info

Publication number
MX2020005005A
MX2020005005A MX2020005005A MX2020005005A MX2020005005A MX 2020005005 A MX2020005005 A MX 2020005005A MX 2020005005 A MX2020005005 A MX 2020005005A MX 2020005005 A MX2020005005 A MX 2020005005A MX 2020005005 A MX2020005005 A MX 2020005005A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cell populations
selective expansion
agents
Prior art date
Application number
MX2020005005A
Other languages
English (en)
Inventor
Orit Foord
Hui Shao
Aya Jakobovits
Daulet Kadyl Satpayev
Yifeng Frank Jing
Jason Michael Romero
Mary Michael Brodey
Matthew Ian Hoopes
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of MX2020005005A publication Critical patent/MX2020005005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a agentes que se unen a un epítopo específico de un TCR ?d d3. Tales agentes pueden ser, de modo no taxativo, un anticuerpo o fragmento de este. En la presente también se describen métodos para usar los agentes, p. ej., para expandir o expandir selectivamente las células T ?d d3. En la presente también se describen métodos para usar las células T ?d d3 expandidas para el tratamiento de un sujeto que lo necesita.
MX2020005005A 2017-11-15 2018-11-15 Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas. MX2020005005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586782P 2017-11-15 2017-11-15
PCT/US2018/061384 WO2019099744A1 (en) 2017-11-15 2018-11-15 METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
MX2020005005A true MX2020005005A (es) 2020-08-27

Family

ID=64755702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005005A MX2020005005A (es) 2017-11-15 2018-11-15 Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas.

Country Status (11)

Country Link
US (1) US20230257462A1 (es)
EP (1) EP3710472A1 (es)
JP (1) JP2021502816A (es)
KR (1) KR20200098518A (es)
CN (1) CN111801349A (es)
AU (1) AU2018370120C1 (es)
CA (1) CA3082818A1 (es)
IL (1) IL274640A (es)
MX (1) MX2020005005A (es)
SG (1) SG11202004506WA (es)
WO (1) WO2019099744A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218747A1 (en) 2018-12-03 2022-07-14 Adicet Bio, Inc. Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof
US20220154144A1 (en) * 2019-04-26 2022-05-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
EA031322B1 (ru) 2010-01-22 2018-12-28 Дау Агросайенсиз Ллс Клетка или клеточная линия для экспрессии экзогенных нуклеотидных последовательностей и применение клетки или клеточной линии
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
EP2684600A1 (en) 2012-07-10 2014-01-15 Laboratoires Meiners Sarl Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes
ES2750550T3 (es) 2013-03-01 2020-03-26 Univ Minnesota Corrección de gen a base de TALEN
CN117143814A (zh) 2014-11-17 2023-12-01 阿迪塞特治疗公司 工程化的γδ T细胞
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive

Also Published As

Publication number Publication date
IL274640A (en) 2020-06-30
KR20200098518A (ko) 2020-08-20
US20230257462A1 (en) 2023-08-17
AU2018370120C1 (en) 2024-05-30
WO2019099744A1 (en) 2019-05-23
CN111801349A (zh) 2020-10-20
EP3710472A1 (en) 2020-09-23
SG11202004506WA (en) 2020-06-29
AU2018370120A1 (en) 2020-06-25
CA3082818A1 (en) 2019-05-23
JP2021502816A (ja) 2021-02-04
AU2018370120B2 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
SG11201906780SA (en) Bcma-targeting antibody and use thereof
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
MY191649A (en) Antibodies to tigit
MX2019007021A (es) Anticuerpos il-11ra.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MY194184A (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
AR105433A1 (es) Métodos para mejorar la eficacia y expansión de las células inmunes
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
NZ724229A (en) Anti-egfrviii antibodies and uses thereof
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2020010946A (es) Anticuerpos multiespecificos y usos del mismo.
SG10201803780UA (en) Methods and compositions for sustained immunotherapy
SG10201907901XA (en) Antibodies, uses & methods
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
IL288607A (en) High affinity anti-cd3 antibodies and methods for their creation and use
MX2021001703A (es) Polipeptidos de union a ox40 y sus usos.
CL2023003182A1 (es) Receptores químericos de steap1 y métodos de uso de los mismos